Lilly's oral GLP-1 Foundayo shows cardiovascular non-inferiority in largest diabetes trial to date
Eli Lilly (NYSE: LLY) has presented detailed results from the Phase III ACHIEVE-4 trial showing its oral GLP-1 receptor agonist Foundayo (orforglipron) met the primary endpoint of non-inferiority on major adverse cardiovascular events (MACE) against titrated insulin glargine, in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
Results were presented at the European Association for the Study of Diabetes (EASD) annual meeting in Milan and published in The Lancet.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze